Pharmaceuticals

Global Neutropenia Biologic Drug Treatment Industry Trends and Growth Forecast for 2026–2030

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Neutropenia Biologic Drug Treatment Market Across 2026–2030?

The neutropenia biologic drug treatment market size has witnessed substantial growth in recent years. It is projected to expand from $14.78 billion in 2025 to $15.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The market’s expansion in prior periods can be attributed to an increase in cancer chemotherapy usage, the introduction of filgrastim-based therapies, a rise in hospitalizations related to infections, the uptake of supportive oncology care, and the standardization of hospital protocols.

The neutropenia biologic drug treatment market size is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $20.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This projected growth during the forecast period can be primarily attributed to several factors, including a growing oncology patient demographic, increased penetration of biosimilars, a rising demand for long-acting drug formulations, the broadening of outpatient cancer care services, and an increase in healthcare spending. Key trends anticipated during the forecast timeframe encompass the expanding utilization of G-CSF biologics, the increasing embrace of long-acting biologic treatments, advancements in the management of chemotherapy-induced neutropenia, a strategic emphasis on biosimilars to lower costs, and the wider distribution through hospital and oncology pharmacies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp

What Drivers Are Shaping The Future Growth Of The Neutropenia Biologic Drug Treatment Market?

An increasing global incidence of cancer is expected to fuel the expansion of the market for neutropenia biologic drugs. This surge in cancer diagnoses, coupled with more individuals opting for chemotherapy, has led to a rise in neutropenia cases. For example, data from July 2024 by the Australian Institute of Health and Welfare, an Australian government body, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 daily cases, with males accounting for roughly 55% of these diagnoses. Consequently, the escalating worldwide cancer incidence rates are projected to stimulate demand within the neutropenia biologic drug treatment market in the coming years.

What Segmentation Levels Are Considered In The Neutropenia Biologic Drug Treatment Market?

The neutropenia biologic drug treatment market covered in this report is segmented –

1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim

2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

What Trends Are Projected To Affect The Neutropenia Biologic Drug Treatment Market?

Leading companies in the neutropenia biologic drug treatment sector are developing biosimilars to offer more affordable alternatives to current biologics. Biosimilars are biologic drugs designed to be nearly identical to an already approved reference biologic, with no significant differences in safety or effectiveness. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, aimed at treating and preventing febrile neutropenia in patients undergoing chemotherapy. It binds to specific receptors on hematopoietic cells, stimulating the proliferation and differentiation of neutrophil precursors in the bone marrow. This action increases the production of neutrophils, which are crucial for fighting infections, particularly in patients undergoing myelosuppressive chemotherapy, thereby reducing the incidence of febrile neutropenia associated with cancer treatments.

Which Leading Firms Are Contributing To The Growth Of The Neutropenia Biologic Drug Treatment Market?

Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

Read the full neutropenia biologic drug treatment market report here:

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

Which Geographic Regions Are Influencing Demand In The Neutropenia Biologic Drug Treatment Market?

North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neutropenia Biologic Drug Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3456&type=smp

Browse Through More Reports Similar to the Global Neutropenia Biologic Drug Treatment Market 2026, By The Business Research Company

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Pegfilgrastim Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market

Orthopedic Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthopedic-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795